101 results
S-8
EX-23.1
TRML
Tourmaline Bio Inc
19 Mar 24
Registration of securities for employees
5:10pm
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in this Registration Statement
S-8
TRML
Tourmaline Bio Inc
19 Mar 24
Registration of securities for employees
5:10pm
.
Consent of Deloitte & Touche LLP, independent registered public accounting firm of Tourmaline Bio, Inc.
Consent of Cooley LLP. Reference is made to Exhibit
8-K
EX-1.1
9imcd2o36kxp2luil5
26 Jan 24
Other Events
4:12pm
424B5
sdrf 8zi149fwpbtp
26 Jan 24
Prospectus supplement for primary offering
4:08pm
424B5
xpd2yhnhy 2yoshuo83
24 Jan 24
Prospectus supplement for primary offering
9:20pm
8-K
EX-99.1
ekwl6ud
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
fpy3r2vrb4 9u6
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.1
6kb45j 2w2xzef0f
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
EX-99.1
m9nh d3k8t
14 Dec 23
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
8:27am
S-8
EX-23.2
0714u3
20 Oct 23
Registration of securities for employees
9:23pm
S-8
EX-23.1
0okpe7tj2pccyuyko0
20 Oct 23
Registration of securities for employees
9:23pm
S-8
pibge5ik24u7nr ueu
20 Oct 23
Registration of securities for employees
9:23pm
8-K
EX-23.1
3fhik172umbm6i
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
3tegdoe6za7 8q5
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm